Please login to the form below

Not currently logged in
Email:
Password:

icosapent ethyl

This page shows the latest icosapent ethyl news and features for those working in and with pharma, biotech and healthcare.

Amarin sues FDA over off-label policy

Amarin sues FDA over off-label policy

The lawsuit relates to the company's Vascepa (icosapent ethyl), an omega-3 fatty acid product that is used to reduce elevated levels of triglycerides in the blood.

Latest news

  • Teva launches first generic of GSK's Lovaza in US Teva launches first generic of GSK's Lovaza in US

    Teva said it believes it is the first company to file for approval of generic Lovaza (omega-3-acid ethyl esters capsules) and the first to secure marketing approval, which should ... Aside from GSK, the launch of a lower-priced Lovaza generic in the US

  • Amarin slides as FDA panel votes against fish oil therapy Amarin slides as FDA panel votes against fish oil therapy

    population. By a 9-2 margin, the panel said it would not support approval of the omega-3 fatty acid based Vascepa (icosapent ethyl) as a combination therapy with statin drugs ... One of the claims made by Amarin for Vascepa is that it reduces

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
IGNIFI

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Latest intelligence

Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...
Light_bulb_Stock_Market.jpg
Creativity has lost its worth
Creativity has lost its worth, and sadly it is undermining effectiveness...

Infographics